Master Protocols + Adaptive Platform Trials

Master Protocols + Adaptive Platform Trials

DISCOVER OUR RESEARCH

With the power of new therapies, technologies, and big data, we are at a pivotal moment in clinical research. The opportunity to accelerate the discovery and development of treatments for patients with rare and deadly diseases is within reach.

The Global Coalition for Adaptive Research (GCAR) unites physicians, clinical researchers, advocacy and philanthropic organizations, biotech/pharma, health authorities, and other key stakeholders in healthcare with the intent to leverage master protocols and platform trials.

Master Protocols + Adaptive Platform Trials — Accelerated, Critical Solutions for Patients with Rare & Deadly Diseases

Master Protocols study multiple therapies or multiple disease sub-types simultaneously and/or over time.

Adaptive Platform Trials focus on a disease or condition, rather than a particular intervention. Uniquely designed as a long-standing clinical trial with the ability to test multiple therapies simultaneously against a common control (or standard of care), it can offer new therapies a much faster path for evaluation by leveraging the infrastructure already in place.

As innovative solutions, master protocols and platform trials align diverse stakeholders and provide more efficient, accelerated drug development to support patient care.

They deliver:

PATIENT-CENTRIC INSIGHTS

Creates a learning environment where patients benefit from the latest clinical insights

ACCESSIBILITY

Enables more patients in the trial to receive potentially effective therapies

ACCELERATED TREATMENTS

A shared infrastructure enables multiple therapies in the same trial; new treatments are initiated quickly and results are analyzed in real-time

FLEXIBILITY

Ability to define subsets of patients and update study parameters as the trial progresses via pre-specified algorithms

EFFICIENCY

Allows multiple treatments and combinations to be studied in parallel; optimal sample size and shared control

FEWER PATIENTS REQUIRED

Shared control group enables testing therapies with fewer patients on trial

DECREASED FINANCIAL RISK

Identifies effective treatments or disproves therapies more quickly; reduction of drug development time and cost; eliminating site activation lag time and cost

GAME-CHANGING APPROACH

Uniquely designed as long-standing platforms that can simultaneously test multiple therapies against a common control (standard of care)—game-changing for patients suffering from rare and deadly diseases.

GCAR IS AN EXPERT

Building and Leading Master Protocols + Adaptive Trials

Trial Development

Operational Oversight

Investigator + Patient Engagement

Regulatory Alignment

Industry Integration

Alliance + Adoption

By developing and operationalizing innovative clinical trials with some of the world’s foremost clinical, translational, basic science investigators and trial experts — and as a 501(c)(3) non-profit — GCAR is uniquely positioned to foster the collaboration required to design and sponsor innovative trial designs.

CURRENT COLLABORATIONS + INITIATIVES

Although these large-scale clinical endeavors require significant prospective planning and relationship building, they provide a more efficient distribution of resources, greatly enhance our understanding of disease biology, and accelerate the development of treatments.

BECOME A PARTNER FOR PROGRESS

We welcome partners in our global mission to accelerate progress for patients. 

Let’s do this faster — together.

Learn How

US + INTERNATIONAL TRIAL SITES

GBM AGILE Trial Sites

REMAP-COVID Trial Sites

< 5 %

Survival rates of GBM patients is less than 5% within 5 years of diagnosis

78

Estimated 1 in 78 women develop ovarian cancer during her lifetime

95 %

95% of those affected by Covid-19 report immediate and long-term health issues
Support a Trial Today